INTRODUCTION
============

Afferent loop obstruction (ALO) caused by recurrent cancer (malignant ALO) that arises after pancreaticoduodenectomy (PD) can lead to an increase in internal pressure, which can block the outflow of bile or pancreatic juice. In addition, it often leads to the development of cholangitis or jaundice due to a loss of papillary function \[[@b1-ce-2019-145]\]. Conventionally, malignant ALO that arises after PD has been managed surgically. However, the general condition of patients with recurrent cancer is often not good enough to undergo surgery. Recently, endoscopic self-expandable metal stents (SEMSs) have been widely used to treat malignant gastric outlet obstruction (mGOO), whereas endoscopic SEMS placement for malignant ALO that arises after PD has only been described in case reports. Previously, we reported a case of malignant ALO arising after PD that was successfully treated by endoscopic SEMS placement \[[@b2-ce-2019-145]\]. However, the clinical outcomes of endoscopic SEMS placement for malignant ALO following PD remain to be evaluated. Herein, we report 7 cases of endoscopic SEMS placement for malignant ALO that arose after PD.

CASE REPORT
===========

Patients
--------

In this study, we retrospectively examined the records of 7 patients (3 males, 4 females; median age, 68 years; range, 56--82 years) who underwent endoscopic SEMS placement for malignant ALO that arose after PD at Kobe University Hospital between April 2010 and May 2018. The primary diseases included 5 cases of pancreatic cancer, 1 case of duodenal cancer, and 1 case of bile duct cancer. Subtotal stomach-preserving PD was performed for the primary disease in all cases. The indications for endoscopic SEMS placement included symptoms caused by cholangitis and a distended afferent loop. Six of 7 patients developed fever and elevated levels of biliary enzymes. One patient experienced severe abdominal pain due to marked distention of the afferent loop but did not develop a fever or elevated biliary enzyme levels ([Table 1](#t1-ce-2019-145){ref-type="table"}). The study protocol was in accordance with the Declaration of Helsinki and approved by the ethics committee of Kobe University Hospital (No. 170100).

Diagnosis of malignant afferent loop obstruction
------------------------------------------------

The diagnosis of malignant ALO was determined based on the clinical presentation, laboratory data, and computed tomography (CT) findings of each case. In each case, CT scans revealed marked distention of the afferent loop due to bowel obstruction caused by a recurrent tumor ([Fig. 1A](#f1-ce-2019-145){ref-type="fig"}). Upper gastrointestinal endoscopy was performed to confirm the diagnosis of neoplastic stenosis and manage the case.

Therapeutic technique
---------------------

An endoscope was inserted into the afferent loop ([Fig. 1B](#f1-ce-2019-145){ref-type="fig"}). After reaching the neoplastic stenotic lesion, a guidewire was advanced across the stricture and into the dilated afferent loop. Then, a nasojejunal tube (N-tube) was placed over the guidewire to decompress the dilated afferent loop ([Fig. 1C](#f1-ce-2019-145){ref-type="fig"}). After decompressing the afferent loop, the length and location of the obstruction were accurately evaluated by injecting contrast medium through the N-tube to allow safe and effective endoscopic SEMS placement. Subsequently, the endoscope was inserted into the afferent loop along the N-tube, and an SEMS was deployed across the stricture using the standard through-the-scope technique ([Fig. 1D](#f1-ce-2019-145){ref-type="fig"}). The procedure was performed using a therapeutic gastrointestinal endoscope (GIF 1T260; Olympus Optical Co., Tokyo, Japan) with a 3.7-mm working channel, under conscious sedation. In 6 patients, Niti-S uncovered duodenal stents (Taewoong Medical, Seoul, Korea), measuring 22 mm in diameter and 80, 100, or 120 mm in length, were used. In the remaining patient, an Evolution uncovered duodenal stent (Cook Medical, Bloomington, IN, USA), measuring 22 mm in diameter and 60 mm in length, was used. The expansion of the SEMS and amelioration of the ALO were assessed on CT scans after the SEMS placement.

Definitions
-----------

Clinical success was defined as decompression of the anastomotic proximal afferent loop after SEMS placement combined with symptom relief. The procedure time was defined as the time between the insertion and removal of the endoscope. The severity of adverse events was evaluated according to the American Society for Gastrointestinal Endoscopy's grading system \[[@b3-ce-2019-145]\].

Statistical analysis
--------------------

Results are expressed as medians and ranges or absolute values and percentages. Overall survival was estimated using the Kaplan-Meier method. All analyses were performed using the JMP Pro software version 11.2.0 (SAS Institute, Cary, NC, USA).

Results
-------

The results of this study are summarized in [Table 2](#t2-ce-2019-145){ref-type="table"}. Clinical success was achieved in all 7 cases postoperatively (100%). The median procedure time was 30 min (range, 15--50 min). There were no cases of stent occlusion. After the SEMS placement, 2 of the 7 patients received chemotherapy, while the 5 remaining patients received best supportive care. No adverse events associated with the procedure were encountered in this series. All the patients died of their primary disease, and the median overall survival period was 155 days (range, 96--374 days).

A re-intervention for obstructive jaundice and acute cholangitis was performed in 1 case (case 2). This patient presented with biliary obstruction due to tumor recurrence at a bilioenteric anastomosis at 253 days after SEMS placement. SEMS obstruction was not observed under endoscopy and fluoroscopy. The patient's jaundice and cholangitis were treated by endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting (EUS-HGAS) owing to failed biliary stenting via bilioenteric anastomosis ([Fig. 2](#f2-ce-2019-145){ref-type="fig"}).

DISCUSSION
==========

Endoscopic SEMS placement for malignant ALO that arises after PD has only been reported sporadically in case reports \[[@b3-ce-2019-145]\]. Our case series is the first to focus on the clinical outcomes of endoscopic SEMS placement for malignant ALO that arises after PD.

Malignant ALO following PD can be managed via surgical or non-surgical treatment. While surgery is effective, it is also highly invasive. Many patients with recurrent pancreaticobiliary cancer are not well enough to tolerate surgery. Hence, a non-surgical treatment option is clearly preferable. Previously, malignant ALO had been treated with percutaneous transhepatic biliary drainage (PTBD). However, biliary access can be challenging in patients without jaundice or sufficiently dilated intrahepatic bile ducts. Furthermore, PTBD is known to cause severe adverse events, such as bleeding, bile peritonitis, or ascending cholangitis \[[@b4-ce-2019-145]\]. Endoscopic treatment approaches for ALO have emerged as feasible alternatives to surgery. Recently, endoscopic duodenal SEMS placement has been implemented as an alternative to surgical bypass for the palliation of mGOO in light of its low morbidity and mortality rates. In contrast, endoscopic SEMS placement for malignant ALO has only been reported sporadically in case reports.

During a PubMed search, we found 12 reports (23 patients) on the use of SEMS to treat malignant ALO that arises after PD ([Table 3](#t3-ce-2019-145){ref-type="table"}) \[[@b5-ce-2019-145]-[@b16-ce-2019-145]\]. Clinical success was achieved in all cases, and no adverse events were encountered. Although the data were limited, no cases of SEMS obstruction were found. In addition, none of these previous cases required re-intervention after the SEMS placement. In our case series, no procedure-related adverse events were encountered, the procedure time was not prolonged, and technical success was achieved in all 7 cases. Two of the 7 cases received chemotherapy after the SEMS placement, and both exhibited prolonged survival. There was no clinical suspicion of stent dysfunction in any patient. One patient presented with obstructive jaundice after the SEMS placement. Biliary obstruction occurred due to tumor recurrence at the bilioenteric anastomosis without SEMS obstruction. We determined that direct biliary drainage was required in this situation. However, biliary stenting via the bilioenteric anastomosis failed due to difficult cannulation of the bile duct. In this case, EUS-HGAS was performed as an alternative biliary drainage method, which led to an improvement in the patient's condition. Furthermore, our cases were followed up until death, and no recurrent cholangitis due to obstruction of the SEMS was detected. Thus, our case series exhibited satisfactory clinical outcomes.

We speculated that the two-step approach would be useful for the safe and accurate deployment of endoscopic SEMS for malignant ALO. A N-tube was inserted into the distended afferent loop under fluoroscopy guidance for all cases, and then SEMS was deployed across the stricture after improvement of the clinical condition. This approach has 3 advantages. First, it is more reliable for achieving drainage of the distended afferent loop because the amount of drainage can be checked, which leads to the alleviation of obstructive jaundice and ascending cholangitis. Second, in the determination of the therapeutic strategy, it is important to evaluate whether the bilioenteric anastomosis is involved in the obstruction site. If the bilioenteric anastomosis is obstructed by tumor recurrence, double stenting is required to achieve decompression of both the afferent loop and the biliary duct. However, it is often difficult to diagnose the comorbid obstruction of a bilioenteric anastomosis by CT or ultrasonography. Contrast medium injection through the nasojejunal drain is helpful for assessing bilioenteric obstruction. Finally, evaluating the length and location of the obstruction site after decompressing the afferent loop enables a suitable SEMS placement. This approach may facilitate an accurate diagnosis as well as the selection of therapeutic strategies for ALO with ascending cholangitis.

All the patients in our series were treated using endoscopes of the conventional length. Recently, the use of balloon-assisted endoscopy during SEMS placement for malignant ALO has been reported \[[@b4-ce-2019-145],[@b7-ce-2019-145],[@b9-ce-2019-145],[@b11-ce-2019-145]-[@b14-ce-2019-145],[@b16-ce-2019-145]\]. Shimatani et al. reported a case in which SEMS placement was used to treat ALO caused by cancer recurrence after PD, in which a newly developed, shorttype, double-balloon endoscope (S-DBE) (EI-580BT; Fujifilm, Tokyo, Japan) was used \[[@b13-ce-2019-145]\]. They claimed that the combined use of the new S-DBE, which had a 3.2-mm working channel, and SEMS with a 9 Fr delivery system enabled through-the-scope SEMS placement, which had been previously challenging because the large diameter of the SEMS delivery system did not allow stent deployment through the 2.8-mm working channels of the conventional S-DBE.

If the stricture is long or an angulated loop, endoscopic SEMS placement across the stricture is challenging. Recently, endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) using a lumen-apposing metal stent has been reported \[[@b17-ce-2019-145]-[@b19-ce-2019-145]\]. In addition, we developed a method involving a conventional SEMS with antimigration properties, comprising a largeloop double-pigtail plastic stent within a fully covered biliary SEMS \[[@b20-ce-2019-145]\]. While further studies are needed, EUS-GJ may be considered an alternative treatment for selected malignant ALO cases.

In conclusion, endoscopic SEMS placement may represent an effective and safe treatment for malignant ALO.
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![(A) A computed tomography scan revealed marked distention of the afferent loop, which was suggestive of bowel obstruction caused by a recurrent tumor. (B) An endoscope was inserted into the afferent loop. A neoplastic stenotic lesion blocked further passage of the endoscope. (C) A nasojejunal tube was placed over a guidewire to decompress the dilated afferent loop. (D) A self-expandable metal stent was inserted using the standard through-the-scope technique.](ce-2019-145f1){#f1-ce-2019-145}

![(A) Case 2 presented with obstructive jaundice due to invasive cancer involving a bilioenteric anastomosis after self-expandable metal stent (SEMS) insertion. (B) Endoscopic ultrasound-guided biliary drainage was selected. An echoendoscope was advanced into the stomach, and a 19-gauge fine needle aspiration needle was advanced into a left-sided intrahepatic bile duct (B3). Cholangiography showed stenosis of the bilioenteric anastomosis, and a guidewire was advanced through the stenotic lesion and into the afferent loop. (C) An uncovered SEMS was placed across the stenotic lesion, and a plastic stent was placed through the fistula between the gastric body and the intrahepatic bile duct.](ce-2019-145f2){#f2-ce-2019-145}

###### 

Summary of the Patients

  Case   Age/Sex   Chief complaint   Primary disease     Period from operation (mo)   PS   T-Bil (mg/dL)   AST (U/L)   ALT (U/L)   Alp (U/L)   WBC (count/μL)   CRP (mg/dL)
  ------ --------- ----------------- ------------------- ---------------------------- ---- --------------- ----------- ----------- ----------- ---------------- -------------
  1      63/F      Abdominal pain    Pancreatic cancer   36                           0    1.1             146         86          2,759       3,000            0.1
  2      66/M      Fever             Pancreatic cancer   10                           0    3.0             124         126         802         3,800            3.6
  3      56/F      Fever             Pancreatic cancer   12                           1    2.8             79          84          1,121       12,800           6.9
  4      80/F      Fever             Pancreatic cancer   10                           2    2.5             55          58          1,665       11,600           8.3
  5      61/M      Fever             Pancreatic cancer   14                           2    4.1             50          61          1,031       15,200           9.7
  6      67/M      Fever             Duodenal cancer     41                           0    0.8             69          33          774         8,200            7.0
  7      82/F      Fever             Bile duct cancer    15                           1    6.0             179         109         1,842       10,000           14.5

Alp, alcaline phosphatase; ALT, alanine transaminase; AST, asparate transaminase; CRP, C-reactive protein; PS, performance status; T-Bil, total bililubin; WBC, white blood cell.

###### 

Clinical Outcomes of the Patients

  Case   Clinical success   Treatment time (min)   Adverse events   Stent obstruction   Re-intervention   Overall survival (days)   Treatment after SEMS placement
  ------ ------------------ ---------------------- ---------------- ------------------- ----------------- ------------------------- --------------------------------
  1      Yes                40                     No               No                  No                109                       BSC
  2      Yes                20                     No               No                  Yes               374                       Chemo therapy
  3      Yes                30                     No               No                  No                155                       BSC
  4      Yes                50                     No               No                  No                96                        BSC
  5      Yes                15                     No               No                  No                340                       Chemo therapy
  6      Yes                30                     No               No                  No                187                       BSC
  7      Yes                30                     No               No                  No                132                       BSC

BSC, best supportive care; SEMS, self-expandable metal stent.

###### 

Reported Cases of Self-Expandable Metal Stent Placement for Malignant Afferent Loop Obstruction

  no.   Study                                            Case no.   Age   Sex                 Primary disease     Scope          Stent length (mm)   Stent diameter (cm)   Clinical succes   Adverse event                             Prognosis
  ----- ------------------------------------------------ ---------- ----- ------------------- ------------------- -------------- ------------------- --------------------- ----------------- ----------------------------------------- -----------------------------------------
  1     Burdick et al. (2002) \[[@b5-ce-2019-145]\]      1          47    M                   Ampullary cancer    PCF140         20                  6                     Yes               None                                      ND
  2     Kim et al. (2011) \[[@b6-ce-2019-145]\]          1          52    M                   Pancreatic cancer   CS             24                  6                     Yes               None                                      ND
  3     2                                                62         F     Pancreatic cancer   CS                  20             10                  Yes                   None              ND                                        
  4     Kida et al. (2013) \[[@b7-ce-2019-145]\]         1          68    M                   Pancreatic cancer   Standard DBE   ND                  ND                    Yes               None                                      ND
  5     Kwong et al. (2014) \[[@b8-ce-2019-145]\]        1          75    M                   Pancreatic cancer   EGD            22                  12                    Yes               None                                      After 3 wk died
  6     2                                                58         M     Pancreatic cancer   EGD                 22             9                   Yes                   None              After 6 mo died                           
  7     Sasaki et al. (2014) \[[@b9-ce-2019-145]\]       1          64    M                   Pancreatic cancer   Standard DBE   22                  6                     Yes               None                                      ND
  8     Huang et al. (2015) \[[@b10-ce-2019-145]\]       1          65    M                   Pancreatic cancer   CS             20                  6                     Yes               None                                      After 3 mo died without obstruction
  9     2                                                55         M     Pancreatic cancer   ND                  20             8                   Yes                   None              After 3 mo died without obstruction       
  10    3                                                68         M     Pancreatic cancer   ND                  ND             ND                  Yes                   None              ND                                        
  11    Fujii et al. (2015) \[[@b11-ce-2019-145]\]       1          61    M                   Bile duct cancer    Short DBE      22                  6                     Yes               None                                      After 141 days died
  12    2                                                61         M     Ampullary cancer    Short DBE           22             6                   Yes                   None              After 140 days died                       
  13    Nakahara et al. (2015) \[[@b12-ce-2019-145]\]    1          48    M                   Pancreatic cancer   Standard DBE   22                  12                    Yes               None                                      After 4 mo died without obstruction
  14    2                                                76         M     Bile duct cancer    Standard DBE        22             12                  Yes                   None              After 14 mo died without obstruction      
  15    Shimatani et al. (2016) \[[@b13-ce-2019-145]\]   1          71    F                   Pancreatic cancer   Short DBE      18                  6                     Yes               None                                      ND
  16    Minaga et al. (2016) \[[@b14-ce-2019-145]\]      1          70    M                   Duodenal cancer     Short DBE      18                  8                     Yes               None                                      After 4 mo died without obstruction
  17    Kanno et al. (2018) \[[@b15-ce-2019-145]\]       1          56    M                   Pancreatic cancer   CS             22                  6+9                   Yes               None                                      After 2 mo died without obstruction
  18    2                                                64         M     Bile duct cancer    Prototype           18             10                  Yes                   None              After 12 mo died without obstruction      
  19    3                                                67         M     Pancreatic cancer   CS                  18             8                   Yes                   None              After 4 mo died without obstruction       
  20    Yane et al. (2018) \[[@b16-ce-2019-145]\]        1          76    M                   Pancreatic cancer   Short DBE      22                  12                    Yes               None                                      After 219 days died without obstruction
  21    2                                                65         M     Pancreatic cancer   Short DBE           22             8                   Yes                   None              After 103 days died without obstruction   
  22    3                                                59         F     Pancreatic cancer   Short DBE           22             10                  Yes                   None              After 109 days died without obstruction   
  23    4                                                77         M     Pancreatic cancer   Short DBE           22             6                   Yes                   None              After 84 days died without obstruction    

CS, colonoscope; DBE, double balloon endoscope; EGD, esophagogastroduodenoscope; ND, no data.
